Centessa Pharmaceuticals plc

CNTA

Centessa Pharmaceuticals plc

CNTA

Insider Sentiment (TTM):

Last Purchase:2025-05-16Last Sale:2026-06-24Shares Purchased (TTM):0Shares Sold (TTM):30,453,411

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:146,925,740Shares Outstanding:153,549,733Institutional Ownership Pct.:95.69%

Earnings Market Reaction:

Filing Date:2026-05-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	62	61	51	44	105	383	395	127	118	128	171	145
Short Term Investments	214	233	195	206	179	99	123	167	112	129	110	158
Prepaid Expense And Other Assets Current	16	19	12	9	14	10	16	19	18	21	23	20
Assets Current	349	368	308	300	348	536	568	356	284	315	332	350
Debt Securities Available For Sale Excluding Accru…	257	283	103	153	140	0	-	-	-	-	-	-
Property Plant And Equipment Net	1	1	1	1	1	1	1	1	1	1	1	1
Operating Lease Right Of Use Asset	10	10	10	11	11	11	11	11	12	12	12	12
Deferred Income Tax Assets Net	24	25	25	25	26	27	27	29	29	30	30	27
Other Assets Noncurrent	1	1	2	2	2	2	2	2	2	3	2	2
Assets	642	687	448	492	528	577	610	399	328	360	377	393
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	11	8	9	6	5	7	7	5	7	12	11	11
Accrued Liabilities Current	26	35	20	24	19	51	19	21	20	28	24	23
Liabilities Current	37	43	29	30	24	58	26	27	27	39	35	34
Long Term Debt Noncurrent	110	110	110	110	109	109	76	77	77	76	74	73
Operating Lease Liability Noncurrent	7	8	8	8	8	8	8	9	9	9	9	9
Other Liabilities Noncurrent	0	0	0	0	0	0	0	0	0	0	-	-
Liabilities	154	161	147	147	142	175	111	112	113	124	118	116
Statement Of Stockholders…
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,751	1,710	1,419	1,408	1,399	1,386	1,374	1,120	1,004	987	974	953
Accumulated Other Comprehensive Income Loss Net Of…	1	3	3	2	2	4	2	2	2	1	1	1
Retained Earnings Accumulated Deficit	-1,265	-1,186	-1,120	-1,065	-1,015	-989	-877	-835	-791	-753	-716	-677
Stockholders Equity	487	527	302	345	386	402	499	287	215	236	259	277
Liabilities And Stockholders Equity	642	687	448	492	528	577	610	399	328	360	377	393
Common Stock Par Or Stated Value Per Share	0.002	0	0.002	0.002	0.002	0	0.002	0.002	0.002	0	0.002	0.002
Common Stock Shares Authorized	222	184	222	222	184	184	184	184	153	184	153	153
Common Stock Shares Issued	155	149	134	134	134	133	132	113	100	99	98	95
Shares Outstanding	155	149	134	134	134	133	132	113	100	99	98	95

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	0.23%	-	-	-	-	-	-	-	-	-	-	-
2025	-2.85%	14.67%	37.00%	-8.07%	35.77%	45.53%	28.91%	12.48%	12.21%	-0.63%	0.08%	-
2024	-0.34%	-1.02%	14.04%	29.88%	44.78%	42.33%	9.82%	0.06%	-0.47%	-26.07%	-24.77%	-25.56%
2023	-3.23%	33.12%	71.40%	-2.42%	-9.21%	11.03%	6.57%	7.85%	26.12%	-6.46%	-21.50%	-9.91%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	9.53	8.57	10.57	10.12	14.37	9.25	21.52	13.29	10.37	8.00	9.51	10.35
Quick Ratio	9.11	8.12	10.14	9.81	13.81	9.07	20.92	12.59	9.71	7.47	8.86	9.77
Working Capital	312.11M	324.94M	278.55M	270.67M	323.52M	478.41M	541.96M	328.75M	257.04M	275.71M	297.50M	316.55M
Leverage & Debt
Debt to Equity	0.32	0.30	0.49	0.43	0.37	0.44	0.22	0.39	0.53	0.52	0.45	0.42
Interest Coverage TTM	-22.69	-18.12	-19.21	-19.12	-18.75	-19.93	-15.88	-15.29	-15.71	-17.29	-18.63	-20.91
Debt Ratio	0.24	0.23	0.33	0.30	0.27	0.30	0.18	0.28	0.34	0.34	0.31	0.30
Efficiency & Turnover
Asset Turnover TTM	0.00	0.02	0.03	0.03	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-1.63	-1.46	-1.81	-1.72	-1.68	-2.06	-1.39	-1.44	-1.39	-1.57	-1.63	-1.81
Free Cash Flow Per Share TTM	-1.36	-1.43	-1.35	-1.08	-1.22	-1.24	-1.12	-1.34	-1.50	-1.67	-1.88	-1.93
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-1,384.61%	-1,425.33%	-1,376.10%	-1,304.95%	-	-	-	-	-	-	-
Net Profit Margin TTM	-	-1,316.88%	-1,617.99%	-1,535.82%	-1,492.31%	-	-	-	-	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	-100.00%	-	-	-	-	-	-	-	-	-	-	-
Net Income Growth (1Y)	11.97%	-16.21%	50.50%	46.41%	61.72%	56.04%	2.44%	-8.86%	-34.84%	-30.12%	-66.68%	-62.37%
EPS Growth (1Y)	-2.99%	-29.33%	30.41%	19.92%	21.43%	31.10%	-14.83%	-20.79%	-38.07%	-32.14%	-67.48%	-62.78%
Calculated Values
Free Cash Flow TTM	-209.17M	-194.19M	-181.17M	-144.05M	-162.05M	-142.09M	-130.37M	-146.38M	-149.87M	-160.51M	-181.65M	-183.32M
Net Debt	47.36M	48.14M	59.01M	65.30M	4.10M	-274.28M	-319.33M	-50.87M	-41.42M	-52.33M	-97.50M	-71.92M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-24Sale

Owner: Index, Ventures Life Vi (…

Title: -

Shares: 9,961,789

Price/Share: -

Value: -

Shares Owned: -

Relationship: TenPercentOwner

Ownership: Indirect

2026-06-24Sale

Owner: Medicxi, Ventures Managem…

Title: -

Shares: 19,963,157

Price/Share: -

Value: -

Shares Owned: -

Relationship: TenPercentOwner

Ownership: Indirect

2026-03-26Sale

Owner: Weinhoff, Gregory M

Title: Chief Business Officer

Shares: 23,998

Price/Share: $30.00

Value: $719,940.00

Shares Owned: 65,925

Relationship: Officer

Ownership: Direct

2026-03-26Sale

Owner: Anderson, Karen M.

Title: Chief People Officer

Shares: 41,076

Price/Share: $30.12

Value: $1,237,209.12

Shares Owned: 62,085

Relationship: Officer

Ownership: Direct

2026-03-17Sale

Owner: Anderson, Karen M.

Title: Chief People Officer

Shares: 10,043

Price/Share: $28.10

Value: $282,208.30

Shares Owned: 62,085

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-24	Index, Ventures Life Vi (…	TenPercentOwner	-	Indirect	Sale	9,961,789	-	-	0	4
2026-06-24	Medicxi, Ventures Managem…	TenPercentOwner	-	Indirect	Sale	19,963,157	-	-	0	4
2026-03-26	Weinhoff, Gregory M	Officer	Chief Business Officer	Direct	Sale	23,998	30.00	$719,940.00	65,925	4
2026-03-26	Anderson, Karen M.	Officer	Chief People Officer	Direct	Sale	41,076	30.12	$1,237,209.12	62,085	4
2026-03-17	Anderson, Karen M.	Officer	Chief People Officer	Direct	Sale	10,043	28.10	$282,208.30	62,085	4
2026-03-13	Anderson, Karen M.	Officer	Chief People Officer	Direct	Sale	120,029	26.64	$3,197,572.56	62,085	4/A
2026-03-13	Weinhoff, Gregory M	Officer	Chief Business Officer	Direct	Sale	73,196	26.66	$1,951,405.36	65,925	4
2026-02-02	Hussain, Iqbal J	Officer	Chief Legal Officer	Direct	Sale	38,951	25.15	$979,617.65	57,645	4
2025-12-09	Accardi, Mario Alberto	Officer	President, Orexin Program	Direct	Sale	10,000	28.96	$289,600.00	178,801	4
2025-12-08	Accardi, Mario Alberto	Officer	President, Orexin Program	Direct	Sale	10,000	30.00	$300,000.00	188,801	4
2025-11-17	Bush, Tia L	Officer	Chief Technology & Quality Ofc	Direct	Sale	40,000	28.00	$1,120,000.00	121,503	4
2025-11-17	Hussain, Iqbal J	Officer	General Counsel	Direct	Sale	6,000	27.64	$165,840.00	105,386	4
2025-11-12	Bush, Tia L	Officer	Chief Technology & Quality Ofc	Direct	Sale	40,000	26.00	$1,040,000.00	121,503	4
2025-10-27	Accardi, Mario Alberto	Officer	President, Orexin Program	Direct	Sale	8,000	25.00	$200,000.00	194,394	4
2025-10-15	Hussain, Iqbal J	Officer	General Counsel	Direct	Sale	6,000	22.41	$134,460.00	105,386	4
2025-09-24	Bush, Tia L	Officer	Chief Technology & Quality Ofc	Direct	Sale	35,000	24.00	$840,000.00	121,503	4
2025-09-16	Accardi, Mario Alberto	Officer	President, Orexin Program	Direct	Sale	8,172	21.67	$177,087.24	197,394	4
2025-09-15	Hussain, Iqbal J	Officer	General Counsel	Direct	Sale	6,000	21.85	$131,100.00	105,386	4
2025-09-10	Bush, Tia L	Officer	Chief Technology & Quality Ofc	Direct	Sale	25,000	22.00	$550,000.00	121,503	4
2025-09-10	Hussain, Iqbal J	Officer	General Counsel	Direct	Sale	20,000	22.00	$440,000.00	105,386	4
2025-09-09	Accardi, Mario Alberto	Officer	President, Orexin Program	Direct	Sale	7,000	20.00	$140,000.00	205,566	4
2025-08-15	Hussain, Iqbal J	Officer	General Counsel	Direct	Sale	6,000	17.23	$103,380.00	105,386	4
2025-07-29	Accardi, Mario Alberto	Officer	President, Orexin Program	Direct	Sale	8,322	15.23	$126,744.06	208,163	4
2025-07-25	Weinhoff, Gregory M	Officer	Chief Business Officer	Direct	Sale	10,000	15.56	$155,600.00	122,279	4
2025-07-21	Saha, Saurabh	Director,Officer	Chief Executive Officer	Direct	Sale	55,000	15.92	$875,600.00	221,017	4
2025-07-15	Hussain, Iqbal J	Officer	General Counsel	Direct	Sale	6,000	14.93	$89,580.00	105,386	4
2025-06-25	Weinhoff, Gregory M	Officer	Chief Business Officer	Direct	Sale	10,000	13.86	$138,600.00	122,279	4
2025-06-24	Hussain, Iqbal J	Officer	General Counsel	Direct	Sale	12,000	14.02	$168,240.00	105,386	4
2025-06-24	Accardi, Mario Alberto	Officer	President, Orexin Program	Direct	Sale	15,000	14.00	$210,000.00	216,485	4
2025-06-20	Saha, Saurabh	Director,Officer	Chief Executive Officer	Direct	Sale	55,000	12.63	$694,650.00	221,017	4
2025-05-27	Weinhoff, Gregory M	Officer	Chief Business Officer	Direct	Sale	10,000	12.82	$128,200.00	122,279	4
2025-05-20	Saha, Saurabh	Director,Officer	Chief Executive Officer	Direct	Sale	55,000	12.71	$699,050.00	221,017	4
2025-05-16	Goyal, Arjun	Director	-	Indirect	Purchase	417,646	12.73	$5,316,633.58	462,585	4
2025-05-01	Hussain, Iqbal J	Officer	General Counsel	Direct	Sale	311	14.00	$4,354.00	105,386	4
2025-04-28	Hussain, Iqbal J	Officer	General Counsel	Direct	Sale	2,080	14.01	$29,140.80	105,386	4
2025-04-25	Weinhoff, Gregory M	Officer	Chief Business Officer	Direct	Sale	11,742	13.61	$159,808.62	122,279	4
2025-04-22	Saha, Saurabh	Director,Officer	Chief Executive Officer	Direct	Sale	40,344	12.43	$501,475.92	221,017	4
2025-03-25	Weinhoff, Gregory M	Officer	Chief Business Officer	Direct	Sale	10,000	16.34	$163,400.00	134,021	4
2025-03-20	Saha, Saurabh	Director,Officer	Chief Executive Officer	Direct	Sale	55,000	16.69	$917,950.00	276,017	4
2025-03-17	Hussain, Iqbal J	Officer	General Counsel	Direct	Sale	6,000	16.45	$98,700.00	105,386	4
2025-03-17	Chao, David M	Officer	Chief Administrative Officer	Direct	Sale	7,000	17.29	$121,030.00	225,007	4
2025-02-25	Weinhoff, Gregory M	Officer	Chief Business Officer	Direct	Sale	11,494	15.25	$175,283.50	134,021	4
2025-02-20	Saha, Saurabh	Director,Officer	Chief Executive Officer	Direct	Sale	55,000	16.23	$892,650.00	331,017	4
2025-02-18	Hussain, Iqbal J	Officer	General Counsel	Direct	Sale	6,000	16.48	$98,880.00	105,386	4
2025-02-10	Anderson, Karen M.	Officer	Chief People Officer	Direct	Sale	429	18.99	$8,146.71	54,322	4
2025-02-03	Anderson, Karen M.	Officer	Chief People Officer	Direct	Sale	6,471	16.86	$109,101.06	54,322	4
2025-02-03	Bush, Tia L	Officer	Chief Technology & Quality Ofc	Direct	Sale	11,000	16.86	$185,460.00	121,503	4
2025-01-27	Weinhoff, Gregory M	Officer	Chief Business Officer	Direct	Sale	11,742	16.47	$193,390.74	159,782	4
2025-01-21	Saha, Saurabh	Director,Officer	Chief Executive Officer	Direct	Sale	55,000	15.98	$878,900.00	429,398	4
2025-01-15	Hussain, Iqbal J	Officer	General Counsel	Direct	Sale	6,000	15.29	$91,740.00	118,265	4
2024-12-26	Weinhoff, Gregory M	Officer	Chief Business Officer	Direct	Sale	10,000	17.04	$170,400.00	183,266	4
2024-12-20	Saha, Saurabh	Director,Officer	Chief Executive Officer	Direct	Sale	55,000	17.44	$959,200.00	520,661	4
2024-12-17	Bush, Tia L	Officer	Chief Technology & Quality Ofc	Direct	Sale	17,813	18.00	$320,634.00	147,615	4
2024-12-17	Anderson, Karen M.	Officer	Chief People Officer	Direct	Sale	10,624	17.32	$184,007.68	71,525	4
2024-12-16	Hussain, Iqbal J	Officer	General Counsel	Direct	Sale	77,705	16.39	$1,273,584.95	125,785	4
2024-12-06	Saha, Saurabh	Director,Officer	Chief Executive Officer	Direct	Sale	87,496	18.46	$1,615,176.16	575,661	4
2024-11-25	Weinhoff, Gregory M	Officer	Chief Business Officer	Direct	Sale	10,000	17.66	$176,600.00	183,266	4
2024-11-25	Saha, Saurabh	Director,Officer	Chief Executive Officer	Direct	Sale	299	18.23	$5,450.77	575,661	4
2024-11-22	Saha, Saurabh	Director,Officer	Chief Executive Officer	Direct	Sale	1,671	18.24	$30,479.04	575,661	4
2024-11-13	Saha, Saurabh	Director,Officer	Chief Executive Officer	Direct	Sale	32,023	18.28	$585,380.44	630,661	4
2024-10-25	Weinhoff, Gregory M	Officer	Chief Business Officer	Direct	Sale	11,742	15.38	$180,591.96	183,266	4
2024-10-23	Saha, Saurabh	Director,Officer	Chief Executive Officer	Direct	Sale	2,592	15.32	$39,709.44	630,661	4
2024-09-25	Weinhoff, Gregory M	Officer	Chief Business Officer	Direct	Sale	16,619	15.69	$260,752.11	206,750	4
2024-09-20	Saha, Saurabh	Director,Officer	Chief Executive Officer	Direct	Sale	55,000	16.53	$909,150.00	721,924	4
2024-09-10	Saha, Saurabh	Director,Officer	Chief Executive Officer	Direct	Sale	175,000	16.52	$2,891,000.00	776,924	4
2024-09-10	Weinhoff, Gregory M	Officer	Chief Business Officer	Direct	Sale	30,000	17.00	$510,000.00	223,369	4
2024-09-09	Weinhoff, Gregory M	Officer	Chief Business Officer	Direct	Sale	25,000	15.00	$375,000.00	223,369	4
2024-08-23	Saha, Saurabh	Director,Officer	Chief Executive Officer	Direct	Sale	46,651	12.30	$573,807.30	776,924	4
2024-08-23	Weinhoff, Gregory M	Officer	Chief Business Officer	Direct	Sale	17,802	12.29	$218,786.58	223,369	4
2024-08-22	Saha, Saurabh	Director,Officer	Chief Executive Officer	Direct	Sale	506	12.23	$6,188.38	823,575	4
2024-03-25	Anderson, Karen M.	Officer	Chief People Officer	Direct	Sale	51,160	11.94	$610,850.40	71,525	4
2024-02-01	Rotman, Harris	Officer	SVP Regulatory Affairs	Direct	Sale	4,267	8.10	$34,562.70	62,625	4
2023-09-20	Rotman, Harris	Officer	SVP Regulatory Affairs	Direct	Sale	37,484	6.29	$235,774.36	33,500	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

95.69%

Inst. Shares: 146,925,740

Shares Outstanding: 153,549,733

2025-12-31

101.80%

Inst. Shares: 138,160,213

Shares Outstanding: 135,715,608

2025-09-30

91.31%

Inst. Shares: 122,510,688

Shares Outstanding: 134,163,492

2025-06-30

87.36%

Inst. Shares: 116,787,220

Shares Outstanding: 133,677,405

2025-03-31

86.45%

Inst. Shares: 115,011,404

Shares Outstanding: 133,033,541

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	146,925,740	153,549,733	95.69%
2025-12-31	138,160,213	135,715,608	101.80%
2025-09-30	122,510,688	134,163,492	91.31%
2025-06-30	116,787,220	133,677,405	87.36%
2025-03-31	115,011,404	133,033,541	86.45%
2024-12-31	114,622,339	114,473,449	100.13%
2024-09-30	99,727,272	116,253,902	85.78%
2024-06-30	81,716,851	109,489,184	74.63%
2024-03-31	70,516,111	99,887,720	70.60%
2023-12-31	67,201,512	96,177,578	69.87%
2023-09-30	69,939,209	96,648,110	72.36%
2023-06-30	66,663,128	95,162,734	70.05%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Centessa Pharmaceuticals plc (CNTA) — SEC Financial Statements & Analysis

Centessa Pharmaceuticals plc (CNTA) is a pharmaceutical preparations company, incorporated in X0. Centessa Pharmaceuticals plc trades on Nasdaq as: CNTA. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Centessa Pharmaceuticals plc reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.32x. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.32x

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Centessa Pharmaceuticals plc in?

Centessa Pharmaceuticals plc (CNTA) operates in the Pharmaceutical Preparations industry.

What exchange does CNTA trade on?

Centessa Pharmaceuticals plc (CNTA) trades on the Nasdaq.

Where is Centessa Pharmaceuticals plc incorporated?

Centessa Pharmaceuticals plc is incorporated in United Kingdom.